Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I)
Open Access
- 21 December 2021
- journal article
- research article
- Published by IOS Press in Tumor Biology
- Vol. 43 (1), 341-349
- https://doi.org/10.3233/tub-211533
Abstract
BACKGROUND: Cancer progression is associated with significant systemic clinical manifestations including cachexia induced weight loss and anorexia. Pentoxifylline (PTX) is a drug that has been shown to have multiple beneficial effects in cancer patients through its anti-inflammatory properties. MAIN OBJECTIVE: To evaluate PTX effects on colon cancer patients treated with chemotherapy. PATIENTS and METHODS: Forty metastatic colon cancer patients receiving chemotherapy were enrolled in this randomized study. 17 patients were treated with a full dose of PTX (400 mg TID), 9 patients with a reduced dose PTX (200 mg TID) and 23 served as controls (no PTX). RESULTS: Follow-up evaluations of patients included the following: physical examination; leukopenia determination; weight determination; stomatitis determination; and survival rate. Patients treated with PTX (both full and reduced doses), experienced a significant increase in weight and a reduction in stomatitis relative to the control group. Treatment with PTX also significantly increased patient survival rate. All patients treated with PTX, had a median overall survival (OS) rate of 20.4 months as compared to 13.2 months in the control group. CONCLUSIONS: PTX treatment of colon cancer patients, in addition to chemotherapy, significantly improved survival rates, induced weight gain and reduced stomatitis occurrence –all important parameters of cachexia.Keywords
This publication has 18 references indexed in Scilit:
- Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case seriesOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016
- Pentoxifylline treatment in patients with cancer cachexia: A double-blind, randomized, placebo-controlled clinical trialIbnosina Journal of Medicine and Biomedical Sciences, 2016
- Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factorsCancer Treatment Reviews, 2013
- Pentoxifylline Reduces Tumor Necrosis Factor-α and HIV-Induced Vascular Endothelial ActivationAIDS Research and Human Retroviruses, 2012
- Potentiation of Anticancer Drugs: Effects of Pentoxifylline on Neoplastic CellsInternational Journal of Molecular Sciences, 2011
- Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trialNephrology Dialysis Transplantation, 2011
- 5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicityCancer Chemotherapy and Pharmacology, 2011
- Treatment of cachexia in oncologyIndian Journal of Palliative Care, 2010
- Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease—A randomized placebo-controlled studyAtherosclerosis, 2008
- Cachexia in cancer patientsNature Reviews Cancer, 2002